Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

468

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Metastatic Renal Cell Carcinoma
Trial Locations (14)

15260

University of Pittsburgh, Pittsburgh

17822

Geisinger Clinic, Danville

21205

The Johns Hopkins University, Baltimore

27599

The University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University, Durham

43210

The Ohio State University, Columbus

48109

The Regents of the University of Michigan, Ann Arbor

52242

State University of Iowa, Iowa City

53226

The Medical College of Wisconsin, Inc., Milwaukee

55905

Mayo Clinic, Rochester

66160

University of Kansas Medical Center, Kansas City

70121

Ochsner Clinic Foundation d/b/a Ochsner Health, New Orleans

75390

The University of Texas Southwestern Medical Center, Dallas

84112

University of Utah, Salt Lake City

All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Exelixis

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Duke University

OTHER